Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Karim Fizazi(Université Paris-Sud), Michael A. Carducci, Matthew R. Smith(Massachusetts General Hospital), Ronaldo Damião(Hospital Universitário Pedro Ernesto), Janet E. Brown(Cancer Research UK), Lawrence I. Karsh(The Urology Center of Colorado), Piotr Milecki(Greater Poland Cancer Center), Neal D. Shore(Carolina Urologic Research Center), Michael Rader(Nyack Hospital), Huei Wang(Amgen (United States)), Qi Jiang(Amgen (United States)), Sylvia Tadros(Amgen (United States)), Roger Dansey(Amgen (United States)), Carsten Goessl(Amgen (United States))
The Lancet
February 26, 2011
Cited by 1,958Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis